Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High – Should You Buy?
by Danessa Lincoln · The Markets DailyDianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $46.76 and last traded at $46.60, with a volume of 1021508 shares changing hands. The stock had previously closed at $44.10.
Analyst Ratings Changes
Several research firms have recently issued reports on DNTH. Wedbush reissued an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. HC Wainwright upped their price objective on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Finally, Truist Financial boosted their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $64.43.
Get Our Latest Report on Dianthus Therapeutics
Dianthus Therapeutics Stock Up 5.7%
The stock has a market capitalization of $2.00 billion, a PE ratio of -13.39 and a beta of 1.55. The stock’s 50-day moving average is $41.74 and its 200 day moving average is $33.26.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.
Insider Buying and Selling at Dianthus Therapeutics
In other news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. This represents a 96.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 216,538 shares of company stock valued at $8,283,175. 16.56% of the stock is owned by company insiders.
Institutional Investors Weigh In On Dianthus Therapeutics
A number of large investors have recently added to or reduced their stakes in DNTH. Wellington Management Group LLP boosted its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after buying an additional 2,503,311 shares during the period. Vestal Point Capital LP raised its holdings in Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the period. Braidwell LP acquired a new position in Dianthus Therapeutics during the 3rd quarter worth $32,859,000. Polar Capital Holdings Plc bought a new stake in Dianthus Therapeutics during the third quarter valued at about $29,434,000. Finally, Fairmount Funds Management LLC boosted its holdings in Dianthus Therapeutics by 22.2% during the third quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after acquiring an additional 600,000 shares during the period. Institutional investors own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.